DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2016" report to their offering.
Fragile X Syndrome pipeline therapeutics constitutes close to 27 molecules, out of which approximately 22 molecules are developed by Companies and remaining by Universities and Institutes. Our latest report, Fragile X Syndrome - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Fragile X Syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Fragile X Syndrome Overview
- Therapeutics Development
- Pipeline Products for Fragile X Syndrome - Overview
- Pipeline Products for Fragile X Syndrome - Comparative Analysis
- Fragile X Syndrome - Therapeutics under Development by Companies
- Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes
- Fragile X Syndrome Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Fragile X Syndrome - Products under Development by Companies
- Fragile X Syndrome - Products under Investigation by Universities/Institutes
- Fragile X Syndrome - Companies Involved in Therapeutics Development
- Aelis Farma SAS
- Alcobra Ltd
- AMO Pharma Limited
- Anavex Life Sciences Corp.
- Confluence Pharmaceuticals LLC
- DRI Biosciences Corporation
- Eli Lilly and Company
- GlaxoSmithKline Plc
- GW Pharmaceuticals Plc
- Kareus Therapeutics, SA
- Marinus Pharmaceuticals, Inc.
- Neuren Pharmaceuticals Limited
- Neuron Biopharma SA
- Ovid Therapeutics Inc.
- Sage Therapeutics, Inc.
- Zynerba Pharmaceuticals, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/ls8kfq/fragile_x
